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Abstract
Objective
To examine whether CCR5 32 deletion is associated with long-term response to combination antiretroviral treatment (cART) inΔ
HIV-1 infected patients.
Methods
The genetic sub-study of ANRS CO8 APROCO-COPILOTE cohort included 609 patients who started a protease inhibitor-containing
cART in 1997 99. Patients were considered to have a sustained virological response if all plasma HIV-RNA measurements between–
month 4 and years 3 5 were <500 copies/ml, allowing for a single blip. Virological response was compared between patients–
heterozygous for CCR5 32 ( 32/wt) and wild-type patients (wt/wt) from month 4 to year 3 and month 4 to year 5. Logistic regressionΔ Δ
analysis was used to adjust for baseline demographical data, HIV-RNA, CD4 cell counts, antiretroviral naive status, time spent on
antiretroviral therapy at year 3 and 5 and adherence to treatment (month 4 to year 3 and 5).
Results
Sustained virological response was better in 32/wt than in wt/wt patients: 66  versus 52  up to year 3 (p 0.02), nearly significantΔ % % =
after adjustment to potential cofounders (p 0.07). 32/wt patients had a better virological response, up to year 5, 48  versus 35  (p= Δ % % =
0.01), and remained significantly better, after adjustment, associated with a better virological response up to 5 years post initiation of
cART (p 0.04). There was no association with CD4 response.=
Conclusion
Δ32/wt deletion is associated with a beneficial virological response to cART on the long-term. Whether this association can be a direct
effect of 32/wt deletion remains questionable and needs confirmation in other observational studies.Δ
Author Keywords HIV, antiretroviral therapy, CCR5 32 deletion, virological responseΔ
Introduction
The CCR5 receptor for the -chemokines RANTES (CCL5), MI-1  (CCL3), and MIP-1  (CCL4) is the primary co-receptor forβ α β
macrophage-tropic, non-syncytium inducing (NSI) strains of HIV-1 entry into CD4 cells . The CCR5 32, an allele that contains a[1 ] Δ
32-base pair deletion encoding for a non-functional receptor, protects against infection in homozygotes patients and is associated with
delayed disease progression and death in heterozygous untreated patients , , , .[2 3 4 5 ]
Since 1996, the widespread use of combination antiretroviral therapy (cART) has improved the prognosis of HIV-1 infected patients [6
, . Several studies, whether immunological or virological, have focused on the association between CCR5 genotype and response to7 ]
cART,, at different time frames and have yielded controversial results , , , , , , , , , .[8 9 10 11 12 13 14 15 16 17 ]
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In the setting of the ANRS CO8 APROCO-COPILOTE cohort, we studied the association between the presence of the deletion and the
virological response to cART up to 5 years.
Patients and methods
Patients
The ANRS CO8 APROCO-COPILOTE cohort is a prospective observational study that enrolled 1281 HIV-1 infected adults in 47
hospitals in France starting a protease inhibitor (PI)-containing antiretroviral regimen for the first time in 1997 1999 . Patients had– [18 ]
physical and laboratory examinations at enrolment, after one and four months of cART, and every four months thereafter. Sera and cells
were collected at enrolment and at follow-up visits. A DNA bank was set up in 2002 to study genetic factors associated with response to
treatment or tolerability of the antiretroviral drugs. The study was approved by the Ethics Committee of Hospital Cochin and informed
consent was obtained from all participants.
Methods
Polymerase chain reaction amplification of CCR5 sequences was done using genomic DNA extracted from cryo-preserved
lymphocytes. 32 deletion in the CCR5 gene was detected by amplifying part (735 base pair) of the coding region . CCR5 32Δ [3 ] Δ
heterozygous ( 32/wt) patients were compared to wild-type patients (wt/wt) for their baseline characteristics. Chi-square and WilcoxonΔ
tests were performed to analyze categorical and quantitative variables, respectively. The study was performed in 2005.
CCR5 32 heterozygous ( 32/wt) patients were compared to wild-type patients (wt/wt) for their long term virological andΔ Δ
immunological response to cART. The long term virological response to cART was analysed up to year 3, then to year 5 by logistic
regression. To be included in the year 3 and year 5 analyses, patients should have had respectively at least one data at year 3 /  4 months+ −
and one at year 5 /  4 months. First, a stable sustained virological response was defined as a plasma HIV-1 RNA measurement below the+ −
threshold of detection of 500 copies/ml at all measurements between month 4 (M4) and year 3, and between M4 and year 5. Patients
experiencing only one plasma HIV-1 RNA above 500 copies/ml were considered as meeting the definition of sustained virological
response in this analysis. Secondly, immunological response was assessed using the proportion of patients who achieved a CD4 cell count
greater than 500/mm3 at year 3 and at year 5 . Both models were adjusted for the following baseline characteristics: HIV-1 RNA, CD4[19 ]
cell count, history of antiretroviral treatment at baseline (na ve cART) and during the follow-up (month 4 to year 3 and 5) (medianï
cumulative time under cART between M4 and year 3 or 5), adherence to treatment (month 4 to year 3 and 5) and demographical data (sex,
age, country of birth and group of contamination). The portion of the follow-up spent without treatment was compared in the two groups:
for the 3-year analysis, patients spent 2.5  of the follow-up without treatment (0.3  for CCR5 32 heterozygous patient and 2.9  for% % Δ %
wild type patient p 0.18).=
for the 5-year analysis, patients spent 3.8  of the follow-up without treatment (2.1  for CCR5 32 heterozygous patients and 4.1% % Δ %
for wild type patients p 0.50).=
Assessment of adherence was made by self-administrated questionnaire every year of follow-up defined in the cohort High[20 
adherence refers to patient who always declared being adherent, moderate adherence refers to patient who declared at least one moderate
adherence, low adherence refers to patient who declared one time a non adherence and non adherence refers to patient who declared more
than one time a non adherence.
Quantitative variables with clinically relevant threshold were analyzed as categorical variables, ie CD4 cell count categorized as <=
200/200 350/350 500/>500. Regarding other quantitative variables quartiles, median were considered. These potential confounding– –
factors were used in virological and immunological analyses. Variables were included in the initial multivariable if they were associated
with virological or immunological success in each univariable analysis separately with a P < 0.25. Reduced models resulted from stepwise
selection retaining only variables associated with virological or immunological success at the 0.05 significance level.
Statistical analysis was performed using Statistical Analysis System software (SAS, version 8.2).
RESULTS
Among 1281 patients initially enrolled in the cohort, 609 (48 ) participated in the genetic study set up in 2002. The reason for%
non-participation was lost to follow-up or withdrawal from the cohort (n 259), death (n  84), refusal (n 51), inability to amplify (n 42) or= = = =
unknown (n 236). As the selection was important, we compared baseline characteristics according to whether patients were selected or not=
for this study. Regarding CD4 cells count and undetectable HIV1-RNA at enrolment, no significant difference was noticed between these
two groups. Regarding baseline CD4 cells count, participating patients had a median of 272/mm3 vs 277/mm3 among non participating
patients (p 0.60). For HIV1-RNA, participating patients had a median of 4.5 copies/ml vs 4.5 copies/ml among non participating patients=
CCR5 32 in HIV treated patientsΔ
HIV Med . Author manuscript
Page /3 7
(p 0.13). Among the 609 patients included in the analysis, 97 (16 ) were heterozygous for the CCR5- 32 deletion, 512 (84 ) were= % Δ %
wt/wt, and none were homozygous. At baseline, as compared to wt/wt patients, 32/wt patients were less frequently born in Africa andΔ
were older ( ). They had a lower median HIV-1 RNA and a higher but not significant CD4 cell count ( ).table 1 Table 1 
Patients were followed for a median duration of 76.3 months (Interquartile range 71.5 84.6) and experienced a median of 3 therapeutic–
new lines among heterozygous patients versus 4 among wt/wt (p 0.05). 2679 episodes of treatment modification have been reported=
among 577 patients. 374 among 90 32/wt patients (93 ) and 2305 among 487 wt/wt patients (95 ). In the database, reasons are reportedΔ % %
for 1975 of them. Among these, virological failure was mentioned in 165 cases whose 50 patients with at least one virological failure (4
for 32/wt patients (4 ) and 46 for wt/wt patients (9 )).Δ % %
601 and 576 patients were included respectively in the year 3 and year five analysis. Patients had a median of 9 available HIV-1 RNA
measurements (IQR ) between M4 and M36 and 15 available HIV-1 RNA measurements (IQR ) between M4 and M60.[8 –9 ] [13 –15 ]
From M4 to year 3, 63 patients have a stable virological response (66 ) among patients with the 32 deletion, and 264 (52 ) among% Δ %
those without the deletion (p  0.02). When extended follow-up (M4 to year 5), respectively 44 patients (48 ) and 168 patients (35 )= % %
have a stable virological response (p 0.01).=
At year 5, these differences were also noticed among 32/wt and wt/wt in the two subgroups adjusting for cART-na ve patients (51Δ ï %
vs 45  respectively) and pre treated patients (46  vs 27 ) (this difference was significant p 0.02). The proportion of patients% % % Mantel Haentzel =
with a CD4 cells count greater than 500/mm at year 3 did not significantly differ between the 32 and wild type patients: 55  and 49 3 Δ % %
respectively (p 0.26), nor at year 5: 52  and 54 , respectively (p 0.73).= % % =
After adjustment for confounding factors, 32 deletion significantly associated with a sustained virological response during the periodΔ
M4 to 5 years post-enrolment (p 0.04), and a near significantly associated with a sustained virological response during the period from M4=
to 3 years post-enrolment (p 0.07)( ).= Table 2 
For immunological response 32 deletion was not a significant factor associated with a CD4 count greater than 500/mm3 at year 3 (pΔ =
0.78), nor at year 5 (p 0.15).=
DISCUSSION
Among 609 HIV-1 infected patients started on a PI containing treatment, the frequency of heterozygous patients for CCR5 32 was 16Δ
: it was 4  in patients born in Africa, and 19  in patients born in Europe, similar to previous studies carried out in similar populations % % % [
, , , . The CCR5 32 deletion was associated to a better virological response to cART up to 3 and 5 years. Better virological12 14 16 17 ] Δ
response was not translated into a significantly better immunological response at any term of the study.
At baseline, patients with 32 deletion, were older, had higher CD4 cell count and lower HIV RNA than others. This might beΔ
explained by the effect of CCR5 32 deletion on the natural evolution of HIV infection before these patients started cART. Indeed,Δ
previous studies have shown that the presence of an allele with CCR5 32 confers a delayed progression to the HIV-1 disease in theΔ
absence of cART , . Furthermore, the effect of the deletion may have contributed to a possible selection bias . Indeed, the patients[3 4 ] [19 ]
who could be included in the genetic bank study were those who had survived from 1997 to 2002, and were younger. This bias limits the
interpretation of our results, since only those with a better prognosis could be included.
Previous studies relating to the effect of virological response to cART according to CCR5-  32 deletion provided contradictoryΔ
results: some found a protective role of the CCR5- 32 deletion on virological response to cART , , , , ,  while others didΔ [8 9 10 11 16 17 ]
not find any difference , , , . All have studied relatively short term response, no longer than 2 years. Moreover the[12 13 14 15 ]
characteristics of the patients, clinical and biological status of HIV infection, geographical origin, whether they were pretreated or naive of
cART, adherence to treatment, definition of the virological response (e.g 50 or 500 copies/ml) and time for assessment, varied among the
studies.
Our study is probably the first to assess the impact of this deletion over a long follow-up of a large number of treated patients, and
shows a significant better response after 5 years of treatment in the heterozygous patients. The longest follow-up was 24 months in the
study of Bogner et al. , which found a better virological response to cART, among adherent caucasian patients, na ve of antiretroviral[11 ] ï
treatment.
The discrepancy between short-term and long-term virological response to cART in our study might explain some of the differences
between previous studies. The interpretation of such a moderate effect of the deletion on response to cART would be in favour of either
the absence of an effect among treated patients, or a limited effect only detectable after extensive follow-up.
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In order to take into account differences existing at baseline or occurring during follow-up that might also influence response to cART,
the multivariable analysis was adjusted for potential confounders. Yet, we found that long term virological response was more pronounced
in the heterozygous patients, reflecting a true independent effect of the CCR5 32 deletion in the context of a multifactorial determinismΔ
of long term virological response. Therefore, the potential disadvantage of the innate wild-type profile might be counterbalanced by the
beneficial effect of high adherence level and appropriate time for starting cART.
In view of conflicting results in the previous studies, a meta-analysis including other observational cohorts would bring more evidence
on the long-term effect of this mutation.
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Table 1
Baseline characteristics of the 609 patients included in the APROCO-COPILOTE genetic sub-study according to CCR5 genotype
Characteristics wt/wt (n 512)= Δ32/wt (n 97)= p
Male gender N ( )% 409 (80) 79 (81) 0.72
Age (years) median (IQR) 37 (32 43)– 38 (33 46)– 0.05
Primary risks for HIV infection N( )% 0.03
 Injection drug use 87 (17) 8 (8)
Place of birth N( )% 0.0020
 Europe 366 (71) 85 (88)
 Africa 68 (13) 3 (3)
 Other 24 (5) -
 Missing data 54 (11) 9 (9)
Year of first HAART N ( )% 0.68
 1997 247 (48) 49 (51)
 1998 1999– 265 (52) 48 (49)
AIDS stage N ( )% 114 (22) 20 (21) 0.72
CD4  cell count (/mm )+ 3 median (IQR) 265 (119 403)– 321 (156 466)– 0.06
HIV-RNA (log copies/ml)10 median (IQR) 4.5 (3.7 5.2)– 4.3 (3.6 4.7)– 0.02
No prior antiretroviral treatment N ( )% 226 (44) 43 (44) 0.97
Table 2
Factors associated with stable long-term virological response in 609 patients included in the APROCO-COPILOTE cohort assessed for CCR5 32 deletion * Δ
Variables
Month 4 to year 3 Month 4 to year 5
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
%success OR 95  CI% p OR 95  CI% p %success OR 95  CI% p OR 95  CI% p
CCR5 deletion 0.02 0.09 0.01 0.04
 Δ32/wt 65 1.74 1.10 2.75– 1.59 0.93 2.73– 48 1.77 1.12 2.78– 1.77 1.03 3.04–
 wt/wt 52 1 1 35 1 1
Sex 0.44 0.89 0.67 0.22
 Male 55 1 1 37 1 1
 Female 51 0.85 0.57 1.28– 1.04 0.61 1.76– 35 0.91 0.59 1.40– 1.42 0.81 2.48–
Age (years) 0.23 0.91 0.003 0.33
 <37 52 1 1 31 1 1
 ≥37 57 1.22 0.88 1.68– 0.98 0.67 1.44– 43 1.69 1.19 2.38– 1.22 0.82 1.83–
Origin of birth 0.07 0.14 0.13 0.12
 Africa 45 0.63 0.38 1.04– 0.65 0.36 1.16– 29 0.64 0.36 1.14– 0.61 0.32 1.14–
 Other 57 1 1 39 1 1
Contamination group 0.58 0.69 0.15 0.27
 Homo/bisexual 56 1.10 0.79 1.52– 0.92 0.60 1.41– 40 1.29 0.91 1.82– 1.29 0.82 2.01–
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 Other 54 1 1 34 1 1
HIV-RNA at baseline(log copies/ml)10 0.17 0.09 0.32 0.56
 <3,7 62 1 1 38 1 1
 [3,7 ;4,5[ 49 0.60 0.38 0.94– 0.57 0.34 0.98– 31 0.72 0.44 1.17– 0.68 0.39 1.20–
 [4,5 ; 5,2[ 55 0.77 0.49 1.21– 0.60 0.33 1.07– 39 1.02 0.64 1.63– 0.84 0.45 1.56–
 ≥5,2 53 0.71 0.44 1.13– 0.45 0.23 0.87– 41 1.12 0.69 1.81– 0.71 0.35 1.41–
CD4/mm at baseline3 0.002 0.004 0.04 0.06
 <200 52 0.46 0.27 0.78– 0.36 0.19 0.69– 39 0.77 0.45 1.29– 0.52 0.27 1.00–
 [350 500– [ 46 0.36 0.20 0.62– 0.33 0.17 0.62– 28 0.46 0.26 0.81– 0.40 0.21 0.79–
 [200 350– [ 59 0.61 0.34 1.10– 0.51 0.26 1.01– 38 0.72 0.41 1.27– 0.54 0.27 1.06–
 ≥500 71 1 1 46 1 1
Time spent on cART (months) ** <0.0001 <0.0001 - -
 >35 62 3.70 2.47 5.52– 3.57 2.24 5.69– - - - -
 ≤35 31 1 1
Time spent on cART (months) ** - - <0.0001 <0.0001
 >55 - - - - - 44 5.91 3.34 10.46– 6.15 3.28 11.53–
 ≤55 12 1 1
Adherence 0.001 0.02 0.0011 0.02
 non adherence 30 0.27 0.12 0.62– 0.25 0.09 0.68– 14 0.20 0.06 0.61– 0.28 0.08 0.94–
 low adherence 42 0.44 0.26 0.75– 0.54 0.30 0.99– 24 0.39 0.22 0.71– 0.41 0.21 0.80–
 moderate adherence 56 0.78 0.54 1.13– 0.84 0.55 1.30– 36 0.70 0.48 1.02– 0.68 0.44 1.04–
 high adherence 67 1 1 50 1 1
Prior antiretroviral treatment 0.0003 <0.0001 0.0001 0.002
 yes 63 1.84 1.32 2.55– 2.98 1.85 4.79– 46 1.95 1.38 2.75– 2.18 1.33 3.55–
 no 48 1 1 30 1 1
 *
stable virological response defined as plasma HIV-1 RNA measurement below the threshold of detection of 500 copies/ml at all measurements except once between M4 and year 3 and 5.
 **
cART: combination antiretroviral treatment
